AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 21 min read$BSX

Boston Scientific 3Q 2026: Revenue $5.14B, Net income $582M, EPS $0.4— 10-Q Summary

Boston Scientific reported Q3 2026 revenue of $5.14B, up 1.4% YoY, but net income fell 22.9% to $582M due to a cybersecurity incident. EPS declined 21.6% to $0.4. Nine-month sales rose 6.7%, with Cardiovascular and MedSurg segments driving growth. The company expects to close its Penumbra acquisition in early 2027.

Original reporting
tradingview.com
Published Nov 2, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Boston Scientific 3Q 2026: Revenue $5.14B, Net income $582M, EPS $0.4— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

The earnings miss and operational disruption suggest short‑term downside, but the announced 2027 Penumbra acquisition could provide a longer‑term catalyst.

02

Market read

The earnings release introduces new profit decline data and a cyber‑risk factor, offering traders a fresh basis for short‑term positioning.

03

What to watch

Potential upside from the pending Penumbra acquisition and long‑term cardiovascular pipeline.

Relevance 8/10Novelty 8/10Timing: post‑market

Background

Boston Scientific's Q3 2026 filing includes a detailed breakdown of revenue, profit, and the effect of an August cyber‑attack on operations.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific posted Q3 2026 results showing revenue up 1.4% but net income down 22.9% and EPS down 21.6% amid a cyber‑incident disruption.

Expected impact

downside pressure as the market prices in weaker profit and operational disruption

Evidence & confidence

Revenue growth is modest while profit fell sharply; the cyber‑event signals higher costs and supply risk, prompting investors to sell.

Market effects

Sector

The results may weigh on the broader medical‑device sector, highlighting cyber‑risk exposure.

Regional

U.S. healthcare stocks could see modest pullback following the miss.

Global

Limited; impact confined to investors tracking Boston Scientific and related device makers.

Counterpoint

What could challenge this read

If the cyber‑incident is a one‑off, the stock may be oversold and could rebound on future growth.

Key entities

  • company
    Boston Scientific

    Medical‑device manufacturer reporting Q3 2026 results.

  • company
    Penumbra

    Target of Boston Scientific's planned acquisition.

Read at source← All news

Related articles

NOV 3
$BXMedAI 8/10

Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.

tipranks.com2 min
NOV 2
$BSXMed

A $455 million deal pairs Blackstone with Boston Scientific to help develop a heart pump for a life-threatening emergency.

Blackstone Life Sciences is investing $455 million in Boston Scientific to co-develop the VITALYST heart pump system for cardiogenic shock patients. The system aims to improve efficacy, safety, and ease of use. Blackstone highlights Boston Scientific's cardiovascular expertise and the potential of the VITALYST system to advance mechanical circulatory support technologies.

stocktitan.net2 min
NOV 2
$BSXMed

Boston Scientific Says SIMPLAAFY Met Noninferiority Endpoints After WATCHMAN Implant

Boston Scientific reported that two post-implant drug regimens in the SIMPLAAFY trial met noninferiority endpoints against dual antiplatelet therapy (DAPT) at six months. The study involved 1,857 patients and tested aspirin, a reduced-dose NOAC followed by aspirin, and aspirin with clopidogrel. Both single-drug approaches showed less bleeding and similar ischemic-stroke rates compared to DAPT. The company presented the results at Transcatheter Cardiovascular Therapeutics 2026.

econotimes.com2 min
NOV 2
$BSXLowAI 8/10

After a heart implant, a trial found simpler drug plans had less bleeding and the same stroke rate as two-drug treatment.

A trial found that simpler drug regimens after heart implant procedures had less bleeding and similar stroke rates compared to dual therapy. The WATCHMAN FLX Pro device, by Boston Scientific, was used in the SIMPLAAFY trial, which aims to reduce medication burden and improve post-procedure care for patients with NVAF. The study involved 1,857 patients across 86 sites and followed them for 12 months.

stocktitan.net2 min
NOV 2
$BSXMedAI 9/10

SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

Boston Scientific's WATCHMAN FLX Pro LAAC Device met primary endpoints in the SIMPLAAFY trial, showing non-inferiority of aspirin alone and reduced-dose NOAC regimens compared to DAPT for post-implant care in NVAF patients. The study, presented at TCT 2026, demonstrated lower bleeding rates and equivalent ischemic stroke rates. The device aims to reduce stroke risk and simplify treatment for NVAF patients.

prnewswire.com2 min